Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,917 GBX | -1.24% |
|
-3.03% | +7.15% |
06-24 | Teva launches generic version of Novo Nordisk's diabetes drug Victoza | RE |
06-20 | Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position' | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.15% | 5.46B | |
+54.23% | 815B | |
+44.25% | 654B | |
-6.26% | 354B | |
+21.43% | 337B | |
+10.91% | 302B | |
+18.45% | 247B | |
+2.09% | 229B | |
+13.03% | 219B | |
+9.00% | 171B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Transcript : Hikma Pharmaceuticals PLC, H1 2021 Earnings Call, Aug 06, 2021